세계의 항체 수탁 제조 시장 : 항체 유형, 공급원, 서비스, 최종 사용자별 예측(2025-2030년)

The Antibodies Contract Manufacturing Market was valued at USD 16.34 billion in 2023, expected to reach USD 18.04 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 33.56 billion by 2030.

Antibodies contract manufacturing involves outsourcing the production of antibodies, crucial for therapeutic, diagnostic, and research purposes, to specialized third-party organizations. The necessity for antibodies manufacturing arises from the increasing prevalence of chronic diseases, the growing importance of personalized medicine, and the demand for novel therapeutics, which together underscore the need for scalable, reliable production capabilities. Applications span across pharmaceuticals, biotechnology, academic research, and diagnostics, with end-use predominantly in therapeutic monoclonal antibodies, polyclonal antibodies, biosimilars, and antibody fragments. Key growth influencers include advancements in biotechnology, the rise of biologics, and the expansion of healthcare infrastructure globally. Moreover, technological innovations, such as high-throughput screening and improved expression systems, propel market expansion. Current opportunities lie in untapped markets in emerging economies where demand for advanced healthcare solutions is rising and in niches like bispecific antibodies and antibody-drug conjugates. To seize these opportunities, businesses should focus on strategic partnerships and capacity expansion to accommodate the growing demand for diverse antibody types. However, the market faces challenges such as stringent regulatory frameworks, complex manufacturing processes, the high cost of production, and intellectual property rights issues. Addressing these barriers with efficient quality control systems and streamlined production technologies can mitigate risks. Innovations such as improvements in expression systems (e.g., CHO cells), sustainable production practices, and AI-driven process optimization offer the potential for substantial advancements. Exploring biosimilar antibodies and personalized medicine solutions also presents significant growth avenues. Overall, this market is characterized by rapid technological advancements and competitive dynamics, challenging companies to constantly innovate and adapt. By focusing on sustainable development, operational efficiency, and expanding global reach, businesses can position themselves advantageously within this thriving industry.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibodies Contract Manufacturing Market

The Antibodies Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Development and commercialization need for biopharmaceutical therapeutics
  • Surging need for advanced antibodies for the treatment of chronic diseases
  • Rising preference for personalized medicines
• Market Restraints
  • Concerns regarding development and manufacturing of biologics
• Market Opportunities
  • Growing number of biologics pipelines and growing contract manufacturing service
  • Increasing the R&D budget for the production of antibodies globally
• Market Challenges
  • Complexity of bi/multispecific antibody formats

Porter's Five Forces: A Strategic Tool for Navigating the Antibodies Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibodies Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibodies Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibodies Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibodies Contract Manufacturing Market

A detailed market share analysis in the Antibodies Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibodies Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibodies Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibodies Contract Manufacturing Market

A strategic analysis of the Antibodies Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibodies Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abeomics, Absolute Antibody by LSBio, Advanced ChemTech, Inc., AGC Biologics, Antibodies, Inc., AstraZeneca, Boehringer Ingelheim Biopharmaceuticals GmbH., Bryllan LLC, Catalent, Inc., CD BioSciences, Charles River Laboratories International, Inc., Eli Lilly and Company, FUJIFILM Holdings Corporation, Fujirebio Inc. by H.U. Group Holdings, Inc., Hycult Biotechnology (H.B.T.) B.V., Labcorp Drug Development, Lonza Group Ltd., Merck KGaA, Molecular Depot LLC, Pierre Fabre S.A, Samsung Biologics, Sapphire Bioscience Pty. Ltd., Scantibodies Laboratory, Inc., Synthon International Holding B.V., The Serum Institute of India, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibodies Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Antibody Type, market is studied across Monoclonal Antibodies and Polyclonal Antibodies.
• Based on Source, market is studied across Mammalian and Microbial.
• Based on Services, market is studied across Analytical Development & Quality Control, Cell Line Development, and Process Development.
• Based on End-User, market is studied across Academics & Research Institutions and Biotechnology & Pharmaceuticals Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Development and commercialization need for biopharmaceutical therapeutics
    • 5.1.1.2. Surging need for advanced antibodies for the treatment of chronic diseases
    • 5.1.1.3. Rising preference for personalized medicines
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns regarding development and manufacturing of biologics
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing number of biologics pipelines and growing contract manufacturing service
    • 5.1.3.2. Increasing the R&D budget for the production of antibodies globally
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity of bi/multispecific antibody formats
• 5.2. Market Segmentation Analysis
  • 5.2.1. Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities
  • 5.2.2. End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibodies Contract Manufacturing Market, by Antibody Type

• 6.1. Introduction
• 6.2. Monoclonal Antibodies
• 6.3. Polyclonal Antibodies

7. Antibodies Contract Manufacturing Market, by Source

• 7.1. Introduction
• 7.2. Mammalian
• 7.3. Microbial

8. Antibodies Contract Manufacturing Market, by Services

• 8.1. Introduction
• 8.2. Analytical Development & Quality Control
• 8.3. Cell Line Development
• 8.4. Process Development

9. Antibodies Contract Manufacturing Market, by End-User

• 9.1. Introduction
• 9.2. Academics & Research Institutions
• 9.3. Biotechnology & Pharmaceuticals Companies

10. Americas Antibodies Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Antibodies Contract Manufacturing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Antibodies Contract Manufacturing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Samsung Biologics and LegoChem Biosciences Forge Strategic Alliance to Accelerate ADC Innovation for Solid Tumor Treatment
  • 13.3.2. Aragen Invests USD 30 Million in Bangalore Facility to Boost Biologics Manufacturing Capabilities
  • 13.3.3. KBI Biopharma Unveils SUREmAb, Monoclonal Antibody Development with Accelerated Manufacturing Solutions
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abeomics
• 2. Absolute Antibody by LSBio
• 3. Advanced ChemTech, Inc.
• 4. AGC Biologics
• 5. Antibodies, Inc.
• 6. AstraZeneca
• 7. Boehringer Ingelheim Biopharmaceuticals GmbH.
• 8. Bryllan LLC
• 9. Catalent, Inc.
• 10. CD BioSciences
• 11. Charles River Laboratories International, Inc.
• 12. Eli Lilly and Company
• 13. FUJIFILM Holdings Corporation
• 14. Fujirebio Inc. by H.U. Group Holdings, Inc.
• 15. Hycult Biotechnology (H.B.T.) B.V.
• 16. Labcorp Drug Development
• 17. Lonza Group Ltd.
• 18. Merck KGaA
• 19. Molecular Depot LLC
• 20. Pierre Fabre S.A
• 21. Samsung Biologics
• 22. Sapphire Bioscience Pty. Ltd.
• 23. Scantibodies Laboratory, Inc.
• 24. Synthon International Holding B.V.
• 25. The Serum Institute of India
• 26. WuXi Biologics Co., Ltd.